Review Article

Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature* Paul E. Marik, MD, FACP, FCCM, FCCP; Howard L. Corwin, MD, FACP, FCCM, FCCP Background: Red blood cell (RBC) transfusions are common in intensive care unit, trauma, and surgical patients. However, the hematocrit that should be maintained in any particular patient because the risks of further transfusion of RBC outweigh the benefits remains unclear. Objective: A systematic review of the literature to determine the association between red blood cell transfusion, and morbidity and mortality in high-risk hospitalized patients. Data Sources: MEDLINE, Embase, Cochrane Register of Controlled Trials, and citation review of relevant primary and review articles. Study Selection: Cohort studies that assessed the independent effect of RBC transfusion on patient outcomes. From 571 articles screened, 45 met inclusion criteria and were included for data extraction. Data Extraction: Forty-five studies including 272,596 were identified (the outcomes from one study were reported in four separate publications). The outcome measures were mortality, infections, multiorgan dysfunction syndrome, and acute respiratory distress syndrome. The overall risks vs. benefits of RBC transfusion on patient outcome in each study was classified as (i) risks outweigh benefits, (ii) neutral risk, and (iii) benefits outweigh risks. The odds ratio and 95% confidence interval for each outcome measure was recorded if available. The pooled odds ratios were determined using meta-analytic techniques. Data Synthesis: Forty-five observational studies with a median of 687 patients/study (range, 63–78,974) were analyzed. In 42 of the 45 studies the risks of RBC transfusion outweighed the

I

n recent years red blood cell (RBC) transfusion requirements in western nations has been increasing because of the increasing

*See also p. 2707. From the Division of Pulmonary and Critical Care Medicine (PEM), Thomas Jefferson University, Philadelphia, PA; Section of Critical Care Medicine, Department of Anesthesiology (HLC), Dartmouth-Hitchcock Medical Center, Lebanon, NH. Dr. Corwin is a consultant, has received research support, and is a speaker for Ortho Biotech and Johnson and Johnson PRD. Ortho Biotech and Johnson and Johnson manufacture and distribute Procrit®. Dr. Marik has not disclosed any potential conflicts of interest. For information regarding this article, E-mail: [email protected] Copyright © 2008 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins DOI: 10.1097/CCM.0b013e3181844677

Crit Care Med 2008 Vol. 36, No. 9

benefits; the risk was neutral in two studies with the benefits outweighing the risks in a subgroup of a single study (elderly patients with an acute myocardial infarction and a hematocrit